Our work in Drug Pricing
Testimony on Pharmacy Benefit Managers and the Prescription Drug Supply Chain
Karen Van Nuys spoke to the Senate Finance Committee on March 30, 2023 about the role PBMs play in the pharmaceutical distribution system.
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D
This paper examines how direct-to-consumer advertising (DTCA) for prescription drugs influences utilization by exploiting a large and plausibly exogenous shock to DTCA driven by the introduction of Medicare Part D.Categorized in
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.Categorized in
Schaeffer Co-Director Testifies on PBMs at Senate Congressional Hearing
Erin Trish was part of a panel of witnesses called to testify before the Committee on Commerce, Science and Transportation.
Testimony on Bringing Transparency and Accountability to Pharmacy Benefit Managers
Erin Trish spoke at the Senate Committee on Commerce, Science, & Transportation on February 16, 2023 about the complex and influential role that PBMs play in the pharmaceutical distribution system.
The Impact of Direct-to-Consumer Advertising on Outpatient Care Utilization
Neeraj Sood and colleagues inform the debate about direct-to-consumer advertising by analyzing the effects of ads on office visits and treatment courses for five common chronic conditions.Categorized in
The Urgent Need for a New Generation of Antibiotics
Health policy experts discuss how to ensure the development of new antimicrobials to replace antibiotics and other critical medications that are beginning to lose their effectiveness.
Shame Won’t Solve America’s Obesity Crisis: How Congress Can Help
If saving lives is the objective, then logic, clinical evidence and compassion dictate that Medicare should pay for preventing and treating obesity, starting now.
The Inflation Reduction Act Is Already Killing Potential Cures
The law’s price controls do away with incentives for research and development of life-saving drugs.